Visit COVID-19 resources

[Skip to Content]


NICE issue consultation on draft guideline on macular degeneration

The National Institute for Health and Care Excellence has opened a consultation for their draft guideline on macular degeneration, closing 24 August 2017 at 17:00. The draft guideline provides advice on the management of people with AMD, including pharmacological and non-pharmacological treatments. It also provides guidance on tools available to diagnose and monitor AMD, and what information and support

Macular Society’s call for more funding of research into macular degeneration

Statement from the Macular Society Charity’s landmark report exposing lack of investment in age-related macular degeneration (AMD) is supported by more than 60 of the UK’s foremost sight researchers, ophthalmologists and institutions – Situation described as ‘urgent’ It is a disease with devastating and far-reaching consequences for both patients and their families, and the number of

Clinical Guidelines

RCOphth Clinical Guidelines The aim of College Clinical Guidelines is to identify the best medical evidence, set standards of patient care and ensure patient safety, providing a benchmark for outcomes within which high quality Ophthalmology can be practiced in the UK health service. Our guidelines are systematically generated to help clinicians make better decisions about appropriate healthcare

NHS Clinical Commissioners co-ordinate support from CCGs to review use of Avastin to treat wet AMD

College Statement In response to the public letters sent by the NHS Clinical Commissioners to Secretary of State for Health, cc. Chair of NICE; Simon Stevens at NHS England; and the Chair of the GMC and signed by the Clinical Chair / Lead Clinician of 120 CCGs regarding the use of Avastin to treat wet AMD. The Royal

Use of Avastin (bevacizumab) in age related macular degeneration

Updated Statement from The Royal College of Ophthalmologists In 2011 a working group of The Royal College of Ophthalmologists released a statement regarding the use of Avastin (bevacizumab) in medical ophthalmology. It found that Avastin and Lucentis (ranibizumab) were equally effective in the treatment of neovascular age-related macular degeneration (AMD) and that there was no